Breast Cancer: Challenges in the Treatment and Prodrug Strategies

Area of Science:

• Oncology
• Pharmacology
• Drug Delivery

Background:

• Breast cancer (BC) remains a significant global health challenge due to tumor heterogeneity, drug resistance, and treatment toxicities.
• Conventional therapies often face limitations in efficacy and safety, necessitating novel therapeutic approaches.

Purpose of the Study:

• To review the current status, challenges, and future directions of prodrug development for breast cancer (BC) therapy.
• To highlight the potential of prodrugs to overcome limitations in current BC treatments and improve patient outcomes.

Main Methods:

• This review synthesizes current research on prodrug strategies in breast cancer therapy.
• It examines the design principles, activation mechanisms, and therapeutic applications of prodrugs, particularly concerning the tumor microenvironment (TME).
• The review also discusses the integration of prodrugs with other modalities like immunotherapy and nanotechnology.

Main Results:

• Prodrugs demonstrate potential for improved drug delivery, enhanced efficacy, and reduced systemic toxicity by enabling selective drug release at the tumor site.
• Targeting the tumor microenvironment (TME) with prodrugs can address issues like poor drug solubility and bioavailability.
• Combining prodrugs with immunotherapy and precision medicine shows promise in overcoming drug resistance.

Conclusions:

• Prodrug-based therapies represent a significant advancement in breast cancer treatment, offering a pathway to more effective and personalized interventions.
• Challenges in prodrug design, activation within the TME, and manufacturing need to be addressed for widespread clinical application.
• Future innovations leveraging nanotechnology, AI-driven drug discovery, and personalized medicine are expected to further enhance prodrug efficacy in refractory breast cancer cases.